Terms ending in 2031
Every in-force patent on Pfizer Inc.'s record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,754,072 | Salts and Polymorphs of 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 9,045,487 | Salts and Polymorphs of 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 9,861,638 | Salts and Polymorphs of 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one In force · Low confidence | Pfizer Inc. | In force | Low confidence | |
| US 10,278,974 | Salts and Polymorphs of 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one In force · Low confidence | Pfizer Inc. | In force | Low confidence | |
| US 8,722,884 | Pyrimidine Derivatives for the Treatment of Abnormal Cell Growth In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 9,119,839 | Cancer Treatment In force · Medium confidence | Pfizer Inc. | In force | Medium confidence | |
| US 9,326,945 | Apixaban Formulations In force · High confidence | Bristol-Myers Squibb Company and Pfizer Inc. | In force | High confidence | |
| US 8,580,268 | CPG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 8,278,457 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 9,012,369 | Look-Through Mutagenesis for Developing Altered Polypeptides with Enhanced Properties In force · High confidence | Pfizer, Inc. | In force | High confidence | |
| 10 more term ends in 2031 · Pro | |||||
10 of 20 patents shown. Soonest term end first, then patent number.
Pro members see all 20.
17 of these are in force and held by Pfizer Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.